Page 36 - NTM Insight Pamphlet 2024

Our Accomplishments
• Established Rapid Information Pilot Studies (RIPS)TM, funding scientific research that can quickly provide early-stage answers to important questions and provide the base data for major research grant applications.
• Established the NTM Patient Registry to help accelerate clinical trials for new drugs to treat NTM lung disease.
• Teamed with the American Lung Association to jointly fund research. • Published the first Nutrition Guide for NTM lung disease patients.
• Testified in Congressional Appropriation Hearings on Capitol Hill.
• Secured language amendments for the fiscal 2006 - 2010 budget years directing the National Institutes of Health and the Centers for Disease Control and Prevention to address the concerns of NTM patients.
• Successfully coordinated compassionate use availability for the drug Lamprene/Clofazimine, so patients who have no alternative can receive this life-sustaining medication.
• Worked to ensure that Amikacin, a drug vital to the treatment of NTM lung disease, is prioritized for NTM patients when in short supply.
• Helped ensure a strong patient presence at the FDA’s Patient-Focused Drug Development meeting.
• Worked with industry and other constituents to help bring the first FDA-approved treatment to market for NTM lung disease.
• Partnered with the COPD Foundation to establish the Bronchiectasis & NTM Care Center Network.
INSIGHT - A Patient’s Perspective
34